Please find enclosed outcome of the Board Meeting held on August 4, 2025.
MARICO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marico's Board approved Q1 FY26 results on August 4, 2025. Consolidated revenue from operations grew 23% year-on-year to Rs. 3,259 crore (from Rs. 2,643 crore in Q1 FY25), driven by a strong 27% growth in the India segment (Rs. 2,495 crore) and 12% growth in International (Rs. 764 crore). Consolidated net profit rose about 8% to Rs. 513 crore, with basic EPS of Rs. 3.90. Standalone revenue rose 21% to Rs. 2,281 crore, while standalone net profit jumped sharply to Rs. 777 crore largely due to higher dividend income from subsidiaries (other income of Rs. 474 crore). During the quarter, Marico acquired an additional 8.8% stake in Satiya Nutraceuticals, raising its holding in Plix to 60% on a fully diluted basis. The statutory auditors (B S R & Co. LLP) issued an unqualified limited review report with no qualifications or emphasis of matter.
Strong double-digit revenue growth, particularly in the core India business, is a positive signal for topline momentum. However, profit growth lagged revenue growth, suggesting margin pressure that investors should watch. The consolidated results reflect the real operating performance; standalone earnings are inflated by subsidiary dividends and are not representative of underlying profitability.